French Validation of the Recovery Assessment Scale (RAS-FR)

Condition(s) studied

Investigational drug(s) / intervention(s)

Self-report questionnaires: Participants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved.

Study summary

The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.

Eligibility

Primary outcome measure(s)

• Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability — Baseline and 1 month
  The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.

Trial sites (1)

Other trials for the same condition